{
    "root": "2f3a8f82-8530-3a64-e063-6294a90aa0b0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lovastatin",
    "value": "20250228",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "LOVASTATIN",
            "code": "9LHU78OQFD"
        }
    ],
    "indications": "therapy lovastatin component multiple risk factor intervention individuals dyslipidemia risk atherosclerotic vascular disease . lovastatin used addition diet restricted saturated fat cholesterol part treatment strategy lower total-c ldl-c target levels response diet nonpharmacological measures alone inadequate reduce risk .",
    "contraindications": "patient placed standard cholesterol-lowering diet receiving lovastatin continue diet treatment lovastatin ( ncep treatment guidelines details dietary therapy ) . lovastatin given meals .",
    "warningsAndPrecautions": "lovastatin tablets usp ( white white round , unscored tablets ) containing 40mg lovastatin engraved \u201c cti 143 `` bottle 14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-548-14 ) bottle 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-548-30 ) bottle 90. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-548-90 ) bottle 180. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-548-93 ) bottle 1,000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ( ndc 43063-548-95 ) storage store 20\u00ba 25\u00ba c ( 68\u00ba 77\u00ba f ) . [ usp controlled room temperature . ] lovastatin tablets must protected light stored well-closed , light-resistant child proof container .",
    "adverseReactions": "hypersensitivity component medication . active liver disease unexplained persistent elevations serum transaminases ( ) . concomitant strong cyp3a4 inhibitors ( e.g . , itraconazole , ketoconazole , posaconazole , voriconazole , hiv protease inhibitors , boceprevir , telaprevir , erythromycin , clarithromycin , telithromycin , nefazodone , cobicistat-containing products ) ( , myopathy/rhabdomyolysis ) .",
    "indications_original": "Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk.",
    "contraindications_original": "The patient should be placed on a standard cholesterol-lowering diet before receiving lovastatin and should continue on this diet during treatment with lovastatin (see NCEP Treatment Guidelines for details on dietary therapy). Lovastatin should be given with meals.",
    "warningsAndPrecautions_original": "Lovastatin Tablets USP (white to off white round, unscored tablets) containing 40mg of lovastatin and engraved with \n    \u201cCTI 143\" \n    Bottle of 14........................................................................ (NDC 43063-548-14) \n    Bottle of 30........................................................................ (NDC 43063-548-30) \n    Bottle of 90........................................................................ (NDC 43063-548-90) \n    Bottle of 180...................................................................... (NDC 43063-548-93) \n    Bottle of 1,000................................................................... (NDC 43063-548-95)\n \n                  \n                     \n                     Storage\n                       Store at 20\u00ba to 25\u00ba C (68\u00ba to 77\u00ba F). [See USP Controlled Room Temperature.] Lovastatin Tablets must be protected from light and stored in a well-closed, light-resistant and child proof container.",
    "adverseReactions_original": "Hypersensitivity to any component of this medication.\n                  Active liver disease or unexplained persistent elevations of serum transaminases (see\n \n  WARNINGS).\n\n \n                  Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin ,nefazodone, and cobicistat-containing products) (see\n \n  WARNINGS,\n \n  \n                        Myopathy/Rhabdomyolysis)\n \n  ."
}